Iron deficiency occurs in the vast majority of patients with chronic kidney disease (CKD). The
causes of iron deficiency in these patients are multifactorial. Main factors that contribute to …

One of the important components of successful anemia therapy in patients with end-stage
renal disease (ESRD) treated with recombinant human erythropoietin is the maintenance of …

Iron deficiency has been studied extensively in patients with chronic kidney disease on
hemodialysis therapy. However, few studies looked at iron treatment in the nondialysis …

Before the introduction of erythropoiesis-stimulating agents (ESAs) in 1989, repeated
transfusions given to patients with end-stage renal disease caused iron overload, and the …

Iron deficiency is common in individuals with chronic kidney disease and plays a major role
in the development of anemia. Both oral and intravenous iron agents are available to replete …

Iron deficiency is prevalent in patients with chronic kidney disease (CKD), and use of oral
and intravenous iron in patients with CKD who do not require dialysis might obviate or delay …

Background: Regulation of body iron occurs at cellular, tissue, and systemic levels. In
healthy individuals, iron absorption and losses are minimal, creating a virtually closed …

Optimizing anemia management is the sole indication for intravenous (IV) iron
administration in the patient with chronic kidney disease (CKD): Achieving and maintaining …

Controversies in iron management. Background Iron therapy is required in hemodialysis
patients receiving erythropoietic stimulators in order to achieve the target hemoglobin in the …

In treating moderate to severe anemia of chronic kidney disease (CKD), oral iron is effective
only in a minority of nondialysis patients. Intravenous iron is more effective and can raise …